Mechanisms of action of EGFR tyrosine kinase receptor incorporated in extracellular vesicles

Mechanisms of action of EGFR tyrosine kinase receptor incorporated in extracellular vesicles

EGFR and some of the cognate ligands extensively traffic in extracellular vesicles (EVs) from different biogenesis pathways. EGFR belongs to a family of four homologous tyrosine kinase receptors (TKRs). This family are one of the major drivers of cancer and is involved in several of the most frequen...

Descripció completa

Dades bibliogràfiques
Autors principals:	Zanetti-Domingues, LC, Martin-Fernandez, ML, Huber, V
Format:	Journal article
Idioma:	English
Publicat:	MDPI 2020

Ítems similars

Mechanisms of Action of EGFR Tyrosine Kinase Receptor Incorporated in Extracellular Vesicles
per: Laura C. Zanetti-Domingues, et al.
Publicat: (2020-11-01)

Cooperation and interplay between EGFR signalling and extracellular vesicle biogenesis in cancer
per: Zanetti-Domingues, LC, et al.
Publicat: (2020)

Cooperation and Interplay between EGFR Signalling and Extracellular Vesicle Biogenesis in Cancer
per: Laura C. Zanetti-Domingues, et al.
Publicat: (2020-12-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
per: Xu H, et al.
Publicat: (2019-07-01)

Extracellular Vesicles As Mediators of Resistance to EGFR-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Preclinical Models
per: M. Pérez-Capó, et al.
Publicat: (2023-11-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
per: Lihua Huang, et al.
Publicat: (2015-09-01)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
per: Lu Yang, et al.
Publicat: (2022-06-01)

Radiation-Induced Tumor-Derived Extracellular Vesicles Combined with Tyrosine Kinase Inhibitors: An Effective and Safe Therapeutic Approach for Lung Adenocarcinoma with EGFR19Del
per: Yao Li, et al.
Publicat: (2024-12-01)

HIV Activates the Tyrosine Kinase Hck to Secrete ADAM Protease-Containing Extracellular Vesicles
per: J.-H. Lee, et al.
Publicat: (2018-02-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
per: Cornelius Hempel, et al.
Publicat: (2017-01-01)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
per: Igor Makhlin, et al.
Publicat: (2019-11-01)

An extracellular receptor tyrosine kinase motif orchestrating intracellular STAT activation
per: Katri Vaparanta, et al.
Publicat: (2022-11-01)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
per: Tasia Amelia, et al.
Publicat: (2022-01-01)

Extracellular vesicle-associated tyrosine kinase-like orphan receptors ROR1 and ROR2 promote breast cancer progression
per: Barnabas Irmer, et al.
Publicat: (2023-07-01)

Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
per: Aude I. Ségaliny, et al.
Publicat: (2015-03-01)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
per: Panupong Mahalapbutr, et al.
Publicat: (2024-02-01)

Extracellular Vesicles Act as Nano-Transporters of Tyrosine Kinase Inhibitors to Revert Iodine Avidity in Thyroid Cancer
per: Ramya Lakshmi Rajendran, et al.
Publicat: (2021-02-01)

Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
per: Shannon S. Zhang, MD, et al.
Publicat: (2022-08-01)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> Mutations
per: Kenichi Suda, et al.
Publicat: (2021-06-01)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
per: Xingyuan Li, et al.
Publicat: (2023-10-01)

Mechanisms of receptor tyrosine kinase activation in cancer
per: Zhenfang Du, et al.
Publicat: (2018-02-01)

Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.
per: Kinlin L Chao, et al.
Publicat: (2012-01-01)

Action Mechanisms of Small Extracellular Vesicles in Inflammaging
per: Rocío Mato-Basalo, et al.
Publicat: (2022-04-01)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
per: Marcin Skrzypski, et al.
Publicat: (2017-09-01)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
per: Keigo Kobayashi
Publicat: (2023-12-01)

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
per: Daniel B Costa, et al.
Publicat: (2007-10-01)

EGFR tyrosine kinase activity and Rab GTPases coordinate EGFR trafficking to regulate macrophage activation in sepsis
per: Xuedi Zhang, et al.
Publicat: (2022-11-01)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
per: Zhe Zhang, et al.
Publicat: (2019-11-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance
per: Tim Fischer, et al.
Publicat: (2018-01-01)

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
per: K. K. Laktionov, et al.
Publicat: (2019-06-01)

miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors
per: Tatsuki Shibuta, et al.
Publicat: (2022-06-01)

Proteolytic Cleavage of Receptor Tyrosine Kinases
per: Hao Huang
Publicat: (2021-04-01)

Receptor Tyrosine Kinases — Expanding Horizons
per: Sassan Hafizi
Publicat: (2014-06-01)

Extracellular phosphorylation of a receptor tyrosine kinase controls synaptic localization of NMDA receptors and regulates pathological pain.
per: Kenji Hanamura, et al.
Publicat: (2017-07-01)

Mechanisms of Activation of Receptor Tyrosine Kinases: Monomers or Dimers
per: Ichiro N. Maruyama
Publicat: (2014-04-01)

In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli
per: Jihene Elloumi-Mseddi, et al.
Publicat: (2013-01-01)

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
per: Nathaniel J. Myall, MD, et al.
Publicat: (2025-02-01)

ALGORITHMS FOR MANAGEMENT OF PATIENTS WITH ADVERSE EVENTS ON THERAPY WITH TYROSINE KINASE INHIBITORS EGFR
per: D. D. SAKAEVA
Publicat: (2017-06-01)

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
per: Soomin Kim, et al.
Publicat: (2025-02-01)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
per: Wu Z, et al.
Publicat: (2019-10-01)